FDA approves Zenbexus, first-in-class therapy for advanced multiple myeloma
TL;DR Summary
The FDA approved Bristol Myers Squibb's oral iberdomide (Zenbexus) for advanced multiple myeloma in combination with Darzalex and dexamethasone, marking the debut of a new drug class and the use of a more sensitive measure of cancer remission.
- FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class statnews.com
- BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod Fierce Pharma
- US FDA approves Bristol Myers' blood cancer treatment Reuters
- U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse Bristol Myers Squibb
- Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Stock Fully Priced? Yahoo Finance
Reading Insights
Total Reads
1
Unique Readers
5
Time Saved
2 min
vs 3 min read
Condensed
92%
506 → 38 words
Want the full story? Read the original article
Read on statnews.com